Vol. 44 (1): 4-7, January – February, 2018
doi: 10.1590/S1677-5538.IBJU.2018.0003
DIFFERENCE OF OPINION
Luiz Otavio Torres 1
1 President Elect of the International Society of Sexual Medicine (ISSM)
Testosterone Replacement Therapy (TRT) was – during the last 7 to 8 decades – associated with triggering or worsening of a prostate cancer. A meta-analysis in 2005 of 19 randomized controlled trials showed no statistically significant difference in the diagnosis of prostate cancer in men using TRT or placebo (1). A pooled-analysis of 18 population-based longitudinal studies comprising 3886 men with prostate cancer (PCa) and 6438 matched controls showed no association between endogenous androgen levels and the risk of developing PCa (2).
